Where Confluent Stands With Analysts
Within the last quarter, Confluent (NASDAQ:CFLT) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish…
Stocks Tank After Latest Inflation Data: Here’s What Got Hit The Hardest
Markets traded lower during Friday’s pre-market session following the Bureau of Economic Analysis report on a 5.4% increase in the personal consumption expenditures (PCE) price index for the month of January.
Earnings Scheduled For January 30, 2023
Companies Reporting Before The Bell
• Franklin Resources (NYSE:BEN) is expected to report quarterly earnings at $0.54 per share on revenue of $1.86 billion.
JMP Securities Maintains Market Outperform on Confluent, Lowers Price Target to $33
JMP Securities analyst Patrick Walravens maintains Confluent (NASDAQ:CFLT) with a Market Outperform and lowers the price target from $45 to $33.
Guggenheim Initiates Coverage On Confluent with Buy Rating, Announces Price Target of $29
Guggenheim analyst Howard Ma initiates coverage on Confluent (NASDAQ:CFLT) with a Buy rating and announces Price Target of $29.
Deutsche Bank Upgrades Confluent to Buy, Lowers Price Target to $28
Deutsche Bank analyst Brad Zelnick upgrades Confluent (NASDAQ:CFLT) from Hold to Buy and lowers the price target from $32 to $28.
FBN Securities Initiates Coverage On Confluent with Outperform Rating, Announces Price Target of $30
FBN Securities analyst Shebly Seyrafi initiates coverage on Confluent (NASDAQ:CFLT) with a Outperform rating and announces Price Target of $30.
Benzinga’s Top Ratings Upgrades, Downgrades For January 10, 2023
Upgrades Morgan Stanley upgraded the previous rating for Stem Inc (NYSE:STEM) from Equal-Weight to Overweight. In the third…
Analyst Expectations for Confluent’s Future
Over the past 3 months, 12 analysts have published their opinion on Confluent (NASDAQ:CFLT) stock. These analysts are…
Benzinga’s Top Ratings Upgrades, Downgrades For January 6, 2023
Upgrades Piper Sandler upgraded the previous rating for Aligos Therapeutics Inc (NASDAQ:ALGS) from Neutral to Overweight. Aligos Therapeutics…